Holly Appleberry, DO
Neurology · Pittsburgh, PANPI 1710410741
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Genentech USA, Inc. at 55.1% of the total. Reporting peaked in 2023 at $6,290 and has fallen 98.6% since, to $86 in 2025.
Across 16 payments — averaging $418.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$4K
- Amgen$2K
- Novartis$174
- TG Therapeutics, Inc.$140
- Biogen$125
- AstraZeneca$103
- plus $87 from 1 others
Across 3 payments — averaging $61,846 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$186K
What the payments were for
- Consulting fees$3,10546%
- Speaking & faculty fees$2,25034%
- Travel & lodging$831%
- Food & beverage$1,26319%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 5 | $3,690 |
| Amgen | 4 | $2,382 |
| Novartis | 2 | $174 |
| TG Therapeutics, Inc. | 1 | $140 |
| Biogen | 2 | $125 |
| AstraZeneca | 1 | $103 |
| Ipsen Biopharmaceuticals, Inc | 1 | $87 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,701 in reported general payments places this provider in the 75th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex Pen (4 Pack)Interferon Beta-1a | 14 | $114,470 |
| Teriflunomide | 32 | $95,007 |
| GlatopaGlatiramer Acetate | 30 | $52,275 |
| Dalfampridine ErDalfampridine | 40 | $13,897 |
| Oxcarbazepine | 18 | $1,384 |
| Baclofen | 90 | $1,145 |
| Gabapentin | 79 | $1,042 |
| Duloxetine Hcl | 38 | $1,041 |
| Levetiracetam | 17 | $229 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $150 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 11 | $91 |
| Tamsulosin Hcl | 14 | $76 |
| Fluoxetine Hcl | 21 | $70 |
Paid to pharmacies, not to this prescriber.
Other neurology in Pittsburgh
- Anoopum GuptaPittsburgh$592K
- Thomas ScottPittsburgh$476K
- James ValerianoPittsburgh$416K
- Amber van LaarPittsburgh$413K
- Andrea SynowiecPittsburgh$386K
- Dolores Dominguez SantamariaPittsburgh$265K
- Heather MouryPittsburgh$186K
- Troy DesaiPittsburgh$174K
- Richard KasdanPittsburgh$172K
- David LobasPittsburgh$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.